Maxim Group Upgrades Agile Therapeutics to Buy, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has upgraded Agile Therapeutics (NASDAQ:AGRX) from Hold to Buy and set a price target of $5.
September 22, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agile Therapeutics has been upgraded from Hold to Buy by Maxim Group with a price target of $5.
The upgrade from Hold to Buy by Maxim Group indicates a positive outlook for Agile Therapeutics. The set price target of $5 also suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100